Abstract
There are currently no disease-modifying therapies for the treatment of tauopathies, a group of progressive neurodegenerative disorders that are pathologically defined by the presence of tau protein aggregates in the brain. Current challenges for the treatment of tauopathies include the inability to diagnose early and to confidently discriminate between distinct tauopathies in patients, alongside an incomplete understanding of the cellular mechanisms involved in pathogenic tau-induced neuronal death and dysfunction. In this review, we describe current diagnostic and therapeutic strategies, known drivers of pathogenic tau formation, recent contributions to our current mechanistic understanding of how pathogenic tau induces neuronal death, and potential diagnostic and therapeutic approaches.
Original language | English (US) |
---|---|
Pages (from-to) | 637-648 |
Number of pages | 12 |
Journal | Trends in Pharmacological Sciences |
Volume | 38 |
Issue number | 7 |
DOIs | |
State | Published - Jul 2017 |
Keywords
- Alzheimer's disease
- metabolic syndrome
- neurodegeneration
- tau
- tauopathy
- traumatic brain injury
ASJC Scopus subject areas
- Toxicology
- Pharmacology